Connecting asciminib tolerability to long-term treatment persistence. Comment on: "Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia"

Haematologica · Published 2026-07-23 · DOI 10.3324/haematol.2026.301608

Free full text

Authors (1)

Chan Zhang

Abstract

Not available.

Abstract from DOAJ. Public domain (CC0 1.0).

Read the article at the publisher →

Publication details

Year
2026

Citation

Zhang, C. (2026). Connecting asciminib tolerability to long-term treatment persistence. Comment on: "Favorable tolerability of asciminib versus ATP-competitive tyrosine kinase inhibitors in the ASC4FIRST study of newly diagnosed patients with chronic-phase chronic myeloid leukemia". Haematologica. https://doi.org/10.3324/haematol.2026.301608

Related articles